Bariatric ·
bmi ·
bmi calculator ·
bmi index calculator ·
body mass index ·
diet ·
Energy drink ·
Fasting ·
how to lose weight ·
how to lose weight naturally ·
intermittent fasting ·
mounjaro ·
NHS ·
obesity ·
ozempic ·
weight ·
Weight loss ·
weight loss injections ·
Mounjaro (Tirzepatitde): A Summary of Its Role in Weight Loss
Mounjaro, or tirzepatide, has emerged as a significant medication developed by Eli Lilly and Company. Initially approved in 2022 for adults with type 2 diabetes to regulate blood sugar alongside diet and exercise, it mimics the hormones GLP-1 and GIP, boosting insulin production, reducing liver sugar release, and curbing appetite, which also aids weight loss.
Its expanded use was recognised when the National Institute for Health and Care Excellence (NICE) approved it for obesity treatment on the NHS in December 2024, available through specialist services in England and, for high-need cases, general practitioners. In Scotland, the Scottish Medicines Consortium (SMC) endorsed it for individuals with a BMI of 30 kg/m² or higher, or lower for certain ethnic groups with related conditions, supporting lifestyle changes.
It is administered as a weekly injection with a pre-filled pen, Mounjaro starts at 2.5 mg, increasing to 5 mg after four weeks, and up to 15 mg if necessary, injected into the stomach, thigh, or arm.
Common side effects include nausea and diaorrhea, which typically subside, though serious risks like pancreatitis or thyroid issues require immediate attention. Not suitable for those with specific thyroid cancer or pancreatitis histories, it also affects oral contraceptive efficacy during dose adjustments.
Clinical trials show up to 22.5% weight loss over 72 weeks, sustained over three years, making it a valuable tool when paired with healthy habits, requiring professional guidance for safe use.
Leave a comment